IRWD Q3 2019 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$603M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$131M+99.7% YoY

Gross Profit

$131M99.6% margin

Operating Income

$66M50.2% margin

Net Income

$21M15.7% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

+28.3%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$32M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$334M

Total Liabilities

$487M

Stockholders' Equity

-$153M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$66M	+99.7%
Gross Profit	$131M	$61M	+114.0%
Operating Income	$66M	-$169M	+139.0%
Net Income	$21M	-$174M	+111.8%

Revenue Segments

Collaborative Arrangements

$131M97%

Collaborative Arrangement Co Promotion Agreement

$3M2%

Active Pharmaceutical Ingredient

$643,0000%

Collaborative Arrangement Other Agreements

$346,0000%

Geographic Segments

China Hong Kong And Macau

$32M75%

J

$10M23%

Europe And Other

$526,0001%